Ovarian Cancer is one of the most common gynecologic cancers and the fifth leading cause of cancer-related death among women. The principal reason behind a rise in these deaths is the late diagnosis. Hence, with growing awareness among people, governments of numerous countries are bridging the gap between science & life and actively working on building robust healthcare infrastructure. It, in turn, would enable the patients to have better chances of curing ovarian cancer & avoiding the high rates of morbidity & mortality.
The Global Ovarian Cancer Market is projected to grow at a double-digit CAGR during the forecast period, i.e., 2022-27. The market would be driven primarily by the rapidly increasing cases of ovarian cancer, especially in the aging female population, i.e., surging the demand for accurate, reliable, & timely diagnoses of patients to provide them with adequate treatments. It, in turn, is instigating the leading players in the global market to expand their research & development capacities and introduce new equipment & drugs.
|Study Period||Historical Data: 2017-20|
|Base Year: 2021|
|Forecast Period: 2022-27|
|Regions Covered||North America: The US, Canada, Mexico|
|Europe: Germany, The UK, Germany, France, Italy, Spain, Rest of Europe|
|Asia-Pacific: China, Japan, India, Australia, South East Asia, Rest of Asia-Pacific|
|South America: Brazil, Rest of Latin America|
|Middle East & Africa: South Africa, GCC, Rest of Middle East & Africa|
|Key Companies Profiled||
AstraZeneca PLC, AbbVie Inc., Amgen Inc., Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly and Company, F. Hoffmann-La Roche AG, Glaxosmithkline PLC, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Others
|Unit Denominations||USD Million/Billion|
In addition, the immense support from governments of different countries worldwide through massive investments in R&D activities associated with oncology and favorable policies for practicing medications on patients are also contributing to the growth of the global market.
Many private sector companies & governments are also working on developing robust healthcare facilities to ensure the availability of equipment, drugs, & skilled medical professionals to cater to the varied needs of patients and attract medical tourists.
Moreover, growing awareness among people about such illnesses through different campaigns, healthcare advertisements, and government associations are also propelling the demand for advanced diagnosis & treatment of ovarian cancer patients across several countries worldwide. Furthermore, several research companies are developing medications & therapies that are still undergoing clinical trials, which shall hit the global market in the nearer future.
Nonetheless, the swiftly escalating adoption of combination therapies, owing to their greater OS (overall success) rates & effectiveness than single therapies, further projects lucrative growth prospects for the Global Ovarian Cancer Market through 2027.
Based on Treatment:
Here, chemotherapy rules the Global Ovarian Cancer Market, with platinum-based chemotherapy being SOC (Standard of Care) for several years. The treatment for patients with ovarian cancer depends entirely on the specific tumor type. For Stage-4 patients (advanced ovarian cancer), primary cytoreductive debulking surgery, coupled with platinum-based chemotherapy, is followed as the standard treatment.
In some cases, Avastin (bevacizumab) combined with doublet chemotherapy (carboplatin & paclitaxel) is preferred in order to enhance the overall treatment efficacy & patient survival rate. Besides Avastin, targeted therapies like Zejula (niraparib), Rubraca (rucaparib), and Lynparza (olaparib) collectively have transformed the treatment landscape for ovarian cancer globally.
Based on Diagnosis:
Imaging, one of the most widely used diagnoses, is anticipated to significantly contribute to the growth of the Global Ovarian Cancer Market in the coming years. It owes principally to its efficiency & accuracy in the affected area to measure the tumor size internally. Besides, with the swift escalation in the number of cancer patients worldwide, the need for quicker diagnosis & treatment is instigating the demand for advanced imaging methods to attain early-stage detection and avoid any further spread of tumors.
Moreover, constant advancements in oncology studies and developments in imaging techniques like Magnetic Resonance Imaging (MRI) & Positron Emission Tomography (PET) scans are expanding the capabilities of diagnosis to detect the metastasis & the severity of the disease at ease.
Computed Tomography (CT) scans are swiftly gaining traction for ovarian cancer diagnosis, owing to their capabilities to create detailed pictures of areas inside the body. Although this equipment does not accurately show small ovarian tumors, larger or growing tumors can be seen clearly. CT scans also detect enlarged lymph nodes or signs of cancer spread to other organs.
On the other hand, blood tests are anticipated to demonstrate a steady market growth through 2027, mainly due to constant advancements in medical science and growing awareness among patients about the ease of diagnosis using blood tests. Besides, since ovarian cancer can also possibly elevate the levels of biomarkers that might act as tumor markers, a diagnosis using blood tests can offer a clear picture of the situation and enable medical professionals to make the best decisions.
Based on End-Users:
Of them all, hospitals are anticipated to dominate the Global Ovarian Cancer Market with the largest share during 2022-27. It attributes to rapid infrastructural developments in the healthcare sector globally, i.e., leading to the increasing number of multi-specialty hospitals across different countries to cater to the massive influx of patients seeking diagnosis & treatment and expand medical tourism.
Besides, with the swift acceleration in the inflow of patients at hospitals, the procurement of diagnosis equipment and various drugs for treatment are upscaling at a phenomenal pace. It, in turn, is instigating the leading pharma & biotech companies to expand their production capacities to meet the burgeoning demands across hospitals.
In addition, as several specialty hospitals have multiple laboratories & cancer research centers, the demand for affordable equipment & drugs is rising across these facilities, i.e., playing a prominent role in augmenting the overall market growth.
Geographically, the Global Ovarian Cancer Market expands across:
North America, among all regions, is anticipated to dominate the Ovarian Cancer Market globally with the largest share over the forecast years. The rapidly growing prevalence of ovarian cancer, excellent healthcare facilities, especially across the US & Canada, favorable norms for health insurance reimbursement, and the extensive presence of leading biopharma companies are the prime aspects driving the regional market.
Governments of the US & Canada investing massively in R&D activities for the production of advanced therapies & drugs to treat patients with ovarian cancer and laying out favorable policies for practicing medications on patients are other prominent aspects projected to boost the North America Ovarian Cancer Market in the years to come.
On the other hand, Asia-Pacific is anticipated to demonstrate the fastest market growth through 2027, principally due to the exponentially rising population, with a prominent ratio of females across different countries in the region & their higher probability of getting ovarian cancer. It, in turn, is infusing the demand for advanced diagnosis & therapies for the early detection & treatment of cancer.
Besides, governments of major countries across Asia-Pacific are substantially investing in the healthcare sector for building new world-class hospitals, research institutes, etc., while procuring advanced devices & drugs for the diagnosis & treatment of patients with ovarian cancer.
Among all countries in the region, China would emerge as an area of remunerative opportunities for the leading market players due to the active participation of the government in reducing the prevalence of ovarian cancer across the country by facilitating early diagnosis & treatments.
Key Questions Answered in the Market Research Report:
Frequently Asked Questions
A. The Global Ovarian Cancer Market is projected to witness a double digit CAGR during 2022-27.
A. The rising population of aging females, coupled with swift developments in the healthcare industry, with rigorous research & development activities on advanced diagnosis & therapies for ovarian cancer patients, are projected to drive the Global Ovarian Cancer Market through 2027.
A. Targeted therapies are expected to provide remunerative opportunities for the leading players in the Global Ovarian Cancer Market over the forecast years.